Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease • Series C round led by RTW Investments, LP; RA Capital Management; Fidelity Management & Research Company; and funds and accounts advised by T. Rowe Price Associates, Inc.; and joined by existing investors including The Column Group, Casdin Capital and GV. • Funds will help advance lead gene therapy program in hypertrophic cardiomyopathy (HCM) as well as multiple programs across three therapeutic platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.